新日本製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 化学 | 4931/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2023/05/19 | 日証協 | 248,524株 | +5.34% | 26,362株 | -61.95% | 695,829株 | +2.81% | 84,674株 | -52.11% |
2023/05/12 | 日証協 | 235,924株 | +18.72% | 69,287株 | +1159.76% | 676,800株 | +3.59% | 176,796株 | +507.25% |
2023/05/02 | 日証協 | 198,724株 | +3.44% | 5,500株 | -83.71% | 653,330株 | +1.15% | 29,114株 | -80.43% |
2023/04/28 | 日証協 | 192,124株 | -0.16% | 33,763株 | +549.29% | 645,930株 | -1.38% | 148,750株 | -36.97% |
2023/04/21 | 日証協 | 192,424株 | -4.89% | 5,200株 | -48% | 654,941株 | -8.55% | 236,013株 | -8.46% |
2023/04/14 | 日証協 | 202,324株 | -7.79% | 10,000株 | +37.42% | 716,192株 | -3.13% | 257,822株 | -6.53% |
2023/04/07 | 日証協 | 219,424株 | -11.82% | 7,277株 | -95.85% | 739,363株 | +3.29% | 275,841株 | -30.23% |
2023/03/31 | 日証協 | 248,824株 | -1.19% | 175,186株 | +1197.67% | 715,820株 | -12.1% | 395,342株 | +231.23% |
2023/03/24 | 日証協 | 251,824株 | -16.81% | 13,500株 | -46.71% | 814,366株 | -6.92% | 119,355株 | -28.58% |
2023/03/17 | 日証協 | 302,724株 | -0.23% | 25,331株 | -59.06% | 874,938株 | +0.51% | 167,112株 | +84.89% |
2023/03/10 | 日証協 | 303,417株 | -3.91% | 61,879株 | +866.86% | 870,539株 | -1.37% | 90,385株 | +0.97% |
2023/03/03 | 日証協 | 315,765株 | -0.22% | 6,400株 | +10.33% | 882,669株 | -0.48% | 89,519株 | -26.71% |
2023/02/24 | 日証協 | 316,465株 | -0.88% | 5,801株 | -64.63% | 886,900株 | -1.01% | 122,142株 | -27.57% |
2023/02/17 | 日証協 | 319,265株 | +2.97% | 16,400株 | -21.53% | 895,987株 | -0.01% | 168,639株 | -13.14% |
2023/02/10 | 日証協 | 310,065株 | +3.23% | 20,900株 | +30.43% | 896,071株 | -0.34% | 194,144株 | +315.57% |
2023/02/03 | 日証協 | 300,365株 | -0.22% | 16,024株 | -96.01% | 899,162株 | +0.2% | 46,717株 | -82.78% |
2023/01/27 | 日証協 | 301,041株 | +43.74% | 401,224株 | +4114.1% | 897,352株 | +12.1% | 271,331株 | +461.73% |
2023/01/20 | 日証協 | 209,441株 | +4.38% | 9,521株 | -81.58% | 800,521株 | +0.35% | 48,303株 | -71.64% |
2023/01/13 | 日証協 | 200,658株 | +8.84% | 51,700株 | -19.8% | 797,752株 | +2.03% | 170,302株 | +57.14% |
※株式分割は考慮していませんのでご注意ください。
Page Top